Autoimmune Disease

Accurate and precise non-invasive imaging biomarkers for characterizing and monitoring treatment response.

MRCP+

MRCP+ provides enhanced visualization and quantitative assessment of the biliary tree and pancreatic duct that cannot be obtained via a standard abdominal MRCP or ERCP. Enabling the evaluation of hepatobiliary structures and accurate diagnosis, staging and monitoring disease and treatment response.

The number of strictures measure provided by MRCP+ is the only biomarker under review by the FDA's Biomarker Qualification Program (BQP) for PSC.

Combining MRCP+ with LiverMultiScan

cT1 provides a comprehensive whole liver slice assessment of fibro-inflammation, enabling non-invasive staging of disease activity and treatment response monitoring across several autoimmune liver conditions.

Case Study

A 22-year old male with PSC/AIH overlap syndrome on prednisolone and azathioprine; responded to treatment.

livers showing ct1 reduction over time
22-year old male with PSC/AIH overlap syndrome

Combining LiverMultiScan with the quantitative measures provided by MRCP+, enables precise monitoring of bile duct and parenchymal liver health across a range of autoimmune liver diseases in a single, non-contrast MRI scan.

fusion of liver slice and biliary tree

Speak with our business development team
Our dedicated pharma team is available to discuss your clinical trial needs. Let us know your email address and one of our qualified team will contact you.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.